title: 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma.
abstract: Esophageal squamous cell carcinoma (ESCC) patients are at risk for local failure (LF) following treatment. Predicting tumor regions at high risk for local failure before radiotherapy may increase treatment efficacy by permitting an escalated radiation dose specifically to those regions critical for tumor control. Forty-one patients with non-resectable locally advanced ESCC underwent 18F-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging before concurrent chemoradiotherapy (CCRT). After CCRT, a second (failure) FDG PET/CT was performed in cases of relapse. Failure FDG PET/CT scans were fused to pre-treatment scans to identify tumor regions at high risk for LF. Within a median follow-up time of 26 months, 20 patients (48.8%) had LF. In 19 patients, the failure occurred within a pre-treatment high FDG uptake region; the failure occurred outside these regions in only one patient. Pre-treatment metabolic tumor volume (MTV) was independently associated with LF (P<0.001, HR 1.128, 95% CI: 1.061-1.198). LF was more likely in patients with MTVs ≥27 cm3. In initial PET/CT images, when 50% maximum standardized uptake value (SUVmax) was used as the threshold, delineated subvolumes overlapped LF regions. These results confirm that LF occurs most commonly within pre-treatment high FDG uptake regions.
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Bingjie
authors.initials: B
authors.lastname: Fan
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Pingping
authors.initials: P
authors.lastname: Fan
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Kong
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Xindong
authors.initials: X
authors.lastname: Sun
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Shuqiang
authors.initials: S
authors.lastname: Zhao
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Sun
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Fu
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Jinsong
authors.initials: J
authors.lastname: Zheng
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Shijiang
authors.initials: S
authors.lastname: Wang
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Man
authors.initials: M
authors.lastname: Hu
authors.affiliation: Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.|Departments of Radiation Oncology and Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Jinming
authors.initials: J
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000378:metabolism*; D017211:Treatment Failure
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: FDG PET/CT; concurrent chemoradiotherapy; esophageal squamous cell carcinoma; local failure; radiotherapy